Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

Medera, Inc., (“Medera”), a clinical-stage biotechnology company, announced today that the management team will participate ...

Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...

Therapeutics, Inc. (NASDAQ:APGE), has sold 15,000 shares of the company's common stock, according to a recent SEC filing. The biotech company, currently valued at $2.37 billion, has received a ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.

The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is anticipated to be driven by the company's incretin portfolio, which includes ...

As part of his love-in with infrastructure, the Prime Minister is vowing to 'rip up the rules' and grant planning licences ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...